Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).-Reference-Cited by-同舟云学术

Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5068-5068
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Aggarwal Rahul Raj¹,Thomas George²,Youngren Jack¹,Foye Adam¹,Olson Susan³,Paris Pamela¹,Beer Tomasz M.²,Ryan Charles J.⁴,Witte Owen⁵,Evans Christopher P.⁶,Gleave Martin Edwin⁷,Stuart Josh⁸,Alumkal Joshi J.⁹,Toschi Alexandria¹,Zona Nicole¹,Reiter Robert Evan⁵,Lara Primo¹⁰,Chi Kim N.¹¹,Small Eric Jay¹

Affiliation:

1. UC San Francisco, San Francisco, CA

2. Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

3. Oregon Health & Science University, Portland, OR

4. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

5. UCLA, Los Angeles, CA

6. UC Davis, Sacramento, CA

7. Vancouver Prostate Centre, Vancouver, BC, Canada

8. UC Santa Cruz, Santa Cruz, CA

9. OHSU, Portland, OR

10. UC Davis Comprehensive Cancer Center, Sacramento, CA

11. BC Cancer Agency, Vancouver, BC, Canada